Increase Activity News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Increase activity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Increase Activity Today - Breaking & Trending Today

Peningkatan Aktivitas di Pelabuhan Makassar Bikin Pelindo IV Raih Laba Rp138,37 Miliar

Peningkatan aktivitas di Pelabuhan Soekarno-Hatta, Makassar, membuat PT Pelindo IV (Persero) mencetak laba senilai Rp138,37 miliar di semester I/2021. Perolehan itu lebih tinggi 31,2 persen dibandingkan dengan capaian di periode sama tahun lalu. ....

United States , Sulawesi Utara , Branch Chicago , Branch Ambon , Branch Bitung , Increase Activity , Port Makassar Make , Port Soekarno Hatta , Atomic Number , Director Main , Much Less , Region East Indonesia , According To Him , Port Makassar , Option Under This , Pelindo Iv ,

Abu Erupsi Gunung Sinabung Selimuti 4 Kabupaten/Kota se-Sumut

Abu Erupsi Gunung Sinabung Selimuti 4 Kabupaten/Kota se-Sumut
tribunnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tribunnews.com Daily Mail and Mail on Sunday newspapers.

Sumatera Utara , Gray Eruption Mountain Blanket Districts , Increase Activity , Stands Terrain , City Binjai , City Terrain , Mountain Writer , Village Sigarang Fierce , அதிகரி நடவடிக்கை , மலை எழுத்தாளர் ,

GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update


Published: Apr 19, 2021
 
BEVERLY HILLS, Calif., April 19, 2021 /PRNewswire/  GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company s proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, reported financial results for the fourth quarter and year ended December 31, 2020.
2020 was a year of robust clinical progress and milestone achievements for GT Biopharma, which allowed us to accomplish a major corporate milestone in listing GT Biopharma on NASDAQ at the beginning of 2021.  The emerging data from our GTB-3550 TriKE™ program in hematological malignancies, MDS and AML, are encouraging in both safety and efficacy profiles.  The ongoing data profile has demonstrated significant differences from all other NK cell therapies and NK engager companies, making TriKE™ a monotherapy, off-the-shelf platform therapeutic.  TriKE™ exerts ....

United States , Samir Taneja , Julie Seidel , Cytovance Biologics , Michael Handelman , Philip Werthman , Rajesh Shrotriya , Greg Berk , Susan Roush , Jeffreys Miller , Anthonyj Cataldo , David Castaneda , Beverly Hills , Michael Breen , Brucej Wendel , Iovance Biotherapeutics , Hospital Harvard Medical School , Company Scientific , Stern Investor Relations Inc , Source Gt Biopharma Inc , Exchange Commission , American Society Of Hematology , Development Expenses , University Of Wisconsin , Leadership Team , University Of Minnesota ,